<DOC>
	<DOCNO>NCT01756508</DOCNO>
	<brief_summary>Study eculizumab ability correct reperfusion injury kidney allograft .</brief_summary>
	<brief_title>Eculizumab Prevention Treatment Kidney Graft Reperfusion Injury</brief_title>
	<detailed_description>Based experimental data supportive observation human associate complement gene upregulation ischemic reperfusion injury , hypothesize C5 cleavage key step pathogenesis ischemic reperfusion injury follow transplantation . It hypothesize eculizumab , antibody block C5 cleavage human effective prophylactic agent prevent ischemic reperfusion injury high risk recipient . For test hypothesis , study pilot prospective study test efficacy eculizumab prevent development reperfusion injury contribute graft survival .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>1. age 180 2. weight &gt; 6 kg 3. male female 4. recipient first kidney graft either standard criterion decease live donor 5. end stage renal disease congenital nephrotic syndrome 1 . Blood group ( ABO ) incompatible transplantation 2. presence donorspecific antihuman leukocyte antigen ( HLA ) antibodies 3. multiorgan transplantation 4. previous transplant 5. patient infected HIV , hepatitis C virus ( HCV ) hepatitis B virus ( HBV ) 6. patient haemolyticuraemic syndrome ( HUS )</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>eculizumab</keyword>
	<keyword>kidney transplantation</keyword>
	<keyword>reperfusion</keyword>
	<keyword>rejection</keyword>
	<keyword>infection</keyword>
</DOC>